QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Develops Unique Frozen Formulation of Bria-IMT
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, recently reported the impending clinical use of a novel frozen formulation of the company’s lead cancer drug candidate, Bria-IMT. The new, easy-to-use formulation can be transported more simply to distant locations. An article discussing the company reads, “The company’s frozen formulation allows for the storage of cryopreserved, ready-to-inject Bria-IMT for cold-chain overnight transport to clinical sites where it will be thawed prior to injection in patients. This unique formulation of Bria-IMT has also shown improved potency compared to the old formulation in vitro. Long term, this novel, frozen…